Deoxyelephantopin and isodeoxyelephantopin as potential anticancer agents with effects on multiple signaling pathways

Molecules

Volumn 22, Issue 6, 2017, Pages

  Mehmood, Tahir ^a   Maryam, Amara ^a   Ghramh, Hamed A ^b   Khan, Muhammad ^a   Ma, Tonghui ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

Apoptosis; Cancer; Deoxyelephantopin; Elephantopus carolinianus; Elephantopus scaber; Inflammation; Isodeoxyelephantopin

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYELEPHANTOPIN; LACTONE; PLANT EXTRACT; SESQUITERPENE; TRANSCRIPTION FACTOR;

ANIMAL; APOPTOSIS; ASTERACEAE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; MEDICINAL PLANT; METABOLISM; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASTERACEAE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LACTONES; NEOPLASMS; PLANT EXTRACTS; PLANTS, MEDICINAL; SESQUITERPENES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 85021155627     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22061013     Document Type: Review

References (63)

1. Khan, M.; Maryam, A.; Qazi, J.I.; Ma, T. Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells. Int. J. Biol. Sci. 2015, 11, 1100–1112. [CrossRef] [PubMed]
2. Millimouno, F.M.; Dong, J.; Yang, L.; Li, J.; Li, X. Targeting Apoptosis Pathways in Cancer and Perspectives with Natural Compounds from Mother Nature. Cancer Prev. Res. 2014, 7, 1081. [CrossRef] [PubMed]
3. Khan, M.; Maryam, A.; Zhang, H.; Mehmood, T.; Ma, T. Killing cancer with platycodin D through multiple mechanisms. J. Cell. Mol. Med. 2016, 20, 389–402. [CrossRef] [PubMed]
4. Cragg, G.M.; Newman, D.J. NATURAL PRODUCTS: A CONTINUING SOURCE OF NOVEL DRUG LEADS. Biochim. Biophys. Acta 2013, 1830, 3670–3695. [CrossRef] [PubMed]
5. Prakash, O.; Kumar, A.; Kumar, P.; Ajeet, A. Anticancer Potential of Plants and Natural Products: A Review. Am. J. Pharmacol. Sci. 2013, 6, 104–115. [CrossRef]
6. Cragg, G.M.; Newman, D.J. Plants as a source of anti-cancer agents. J. Ethnopharmacol. 2005, 1, 72–79. [CrossRef] [PubMed]
7. Newman, D.J.; Cragg, G.M.; Snader, K.M. Natural Products as Sources of New Drugs over the Period 1981–2002. J. Nat. Prod. 2003, 7, 1022–1037. [CrossRef] [PubMed]
8. Pratheeshkumar, P.; Sreekala, C.; Zhang, Z.; Budhraja, A.; Ding, S.; Son, Y.O.; Wang, X.; Hitron, A.; Hyun-Jung, K.; Wang, L.; et al. Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets. Anti-Cancer Agents Med. Chem. 2012, 10, 1159–1184. [CrossRef]
9. Amin, A.R.; Kucuk, O.; Khuri, F.R.; Shin, D.M. Perspectives for cancer prevention with natural compounds. J. Clin. Oncol. 2009, 16, 2712–2725. [CrossRef] [PubMed]
10. Rasul, A.; Khan, M.; Ali, M.; Li, J.; Li, X. Targeting Apoptosis Pathways in Cancer with Alantolactone and Isoalantolactone. Sci. World J. 2013, 2013, 248532. [CrossRef] [PubMed]
11. Ogbourne, S.M.; Parsons, P.G. The value of nature's natural product library for the discovery of New Chemical Entities: The discovery of ingenol mebutate. Fitoterapia 2014, 98, 36–44. [CrossRef] [PubMed]
12. Harvey, A.L. Natural products in drug discovery. Drug Discov. Today 2008, 13, 894–901. [CrossRef] [PubMed]
13. Divya, G.S.; Mansoor, K.P.; Rasheed, S.P.; Kumar, A. PPAR gamma agonist: An effect strategy for cancer treatment. JPSI 2013, 5. [CrossRef]
14. Zhang, D.; Haruna, M.; McPhail, A.T.; Lee, K.-H. Cytotoxic germacranolides of Elephantopus carolinianus and the structure and stereochemistry of isodeoxyelephantopin. Phytochemistry 1986, 4, 899–904. [CrossRef]
15. Xu, G.; Liang, Q.; Gong, Z.; Yu, W.; He, S.; Xi, L. Antitumor activities of the four sesquiterpene lactones from Elephantopus scaber L. Exp. Oncol. 2006, 2, 106–109.
16. Zahari, Z.; Jani, N.A.; Amanah, A.; Latif, M.N.A.; Majid, M.I.A.; Adenan, M.I. Bioassay-guided isolation of a sesquiterpene lactone of deoxyelephantopin from Elephantopus scaber Linn. active on Trypanosome brucei rhodesience. Phytomedicine 2014, 3, 282–285. [CrossRef] [PubMed]
17. Wu, T.; Cui, H.; Cheng, B.; Fang, S.; Xu, J.; Gu, Q. Chemical constituents from the roots of Elephantopus scaber L. Biochem. Syst. Ecol. 2014, 54, 65–67. [CrossRef]
18. Koe, X.F.; Lim, E.L.; Seah, T.C.; Amanah, A.; Wahab, H.A.; Adenan, M.I.; Sulaiman, S.F.; Tan, M.L. Evaluation of in vitro cytochrome P450 induction and inhibition activity of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber L. Food. Chem. Toxicol. 2013, 60, 98–108. [CrossRef] [PubMed]
19. Kabeer, F.A.; Sreedevi, G.B.; Nair, M.S.; Rajalekshmi, D.S.; Gopalakrishnan, L.P.; Prathapan, R. Isodeoxyelephantopin from Elephantopus scaber (Didancao) induces cell cycle arrest and caspase-3-mediated apoptosis in breast carcinoma T47D cells and lung carcinoma A549 cells. Chin. Med. 2014, 9, 14. [CrossRef] [PubMed]
20. Kabeer, F.A.; Prathapan, R. phytopharmacological prolife of Elephantopus scabcer. Pharmacologia 2014, 8, 272–285.
21. Beeran, A.A.; Maliyakkal, N.; Rao, C.M.; Udupa, N. The enriched fraction of Elephantopus scaber Triggers apoptosis and inhibits multi-drug resistance transporters in human epithelial cancer cells. Pharmacogn. Mag. 2015, 42, 257–268.
22. Ahmad, A.; Alkarkhi, A.F.M.; Hena, S.; Khim, L.H. Extraction, Separation and Identification of Chemical Ingredients of Elephantopus Scaber L. Using Factorial Design of Experiment. Int. J. Chem. 2009, 1, 36–49. [CrossRef]
23. Ho, W.Y.; Yeap, S.K.; Ho, C.L.; Rahim, R.A.; Alitheen, N.B. Hepatoprotective Activity of Elephantopus scaber on Alcohol-Induced Liver Damage in Mice. Evid. Based Complement. Altern. Med. 2012, 2012, 417953. [CrossRef] [PubMed]
24. Hammer, M.L.A.; Johns, E.A. Tapping an Amazônian plethora: Four medicinal plants of Marajó Island, Pará (Brazil). J. Ethnopharmacol. 1993, 1, 53–75. [CrossRef]
25. Lin, C.-C.; Tsai, C.-C.; Yen, M.-H. The evaluation of hepatoprotective effects of Taiwan folk medicine ‘Teng-Khia-U’. J. Ethnopharmacol. 1995, 2, 113–123. [CrossRef]
26. Hung, H.-F.; Hou, C.-W.; Chen, Y.-L.; Lin, C.-C.; Fu, H.-W.; Wang, J.-S.; Jeng, K.-C. Elephantopus Scaber Inhibits Lipopolysaccharide-Induced Liver Injury by Suppression of Signaling Pathways in Rats. Am. J. Chin. Med. 2011, 4, 705–717. [CrossRef] [PubMed]
27. Kabiru, A. Elephantopus Species: Traditional Uses, Pharmacological Actions and Chemical Composition. Adv. Life Sci. Technol. 2013, 15, 6–13.
28. Yan, G.-R.; Tan, Z.; Wang, Y.; Xu, M.-L.; Yu, G.; Li, Y.; He, Q.-Y. Quantitative proteomics characterization on the antitumor effects of isodeoxyelephantopin against nasopharyngeal carcinoma. Proteomics 2013, 13, 3222–3232. [CrossRef] [PubMed]
29. Su, M.; Chung, H.Y.; Li, Y. Deoxyelephantopin from Elephantopus scaber L. induces cell-cycle arrest and apoptosis in the human nasopharyngeal cancer CNE cells. Biochem. Biophys. Res. Commun. 2011, 2, 342–347.
30. Farha, A.K.; Dhanya, S.R.; Mangalam, S.N.; Geetha, B.S.; Latha, P.G.; Remani, P. Deoxyelephantopin impairs growth of cervical carcinoma SiHa cells and induces apoptosis by targeting multiple molecular signaling pathways. Cell Biol. Toxicol. 2014, 6, 331–343. [CrossRef] [PubMed]
31. Chan, K.C.; Chan, G.; Awang, K.; Kadir, H.A. Deoxyelephantopin from Elephantopus scaber Inhibits HCT116 Human Colorectal Carcinoma Cell Growth through Apoptosis and Cell Cycle Arrest. Molecules 2016, 3, 921–937. [CrossRef] [PubMed]
32. Chan, C.K.; Supriady, H.; Goh, B.H.; Kadir, H.A. Elephantopus scaber induces apoptosis through ROS-dependent mitochondrial signaling pathway in HCT116 human colorectal carcinoma cells. J. Ethnopharmacol. 2015, 168, 291–304. [CrossRef] [PubMed]
33. Mehmood, T.; Maryam, A.; Zhang, H.; Li, Y.; Khan, M.; Ma, T. Deoxyelephantopin induces apoptosis in HepG2 cells via oxidative stress, NF-?B inhibition and mitochondrial dysfunction. BioFactors 2017, 43, 63–72. [CrossRef] [PubMed]
34. Ichikawa, H.; Nair, M.S.; Takada, Y.; Sheeja, D.B.A.; Kumar, M.A.S.; Oommen, O.V.; Aggarwal, B.B. Isodeoxyelephantopin, a Novel Sesquiterpene Lactone, Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis through Suppression of Nuclear Factor-?B (NF-?B) Activation and NF-?B-Regulated Gene Expression. Clin. Cancer Res. 2006, 19, 5910–5918. [CrossRef] [PubMed]
35. Kabeer, F.A.; Sreedevi, G.B.; Nair, M.S.; Rajalekshmi, D.S.; Gopalakrishnan, L.P.; Kunjuraman, S.; Prathapan, R. Antineoplastic effects of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber, on lung adenocarcinoma (A549) cells. J. Integr. Med. 2013, 4, 269–277. [CrossRef] [PubMed]
36. Kerr, J.F.R.; Wyllie, A.H.; Currie, A.R. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics. Br. J. Cancer 1972, 4, 239–257. [CrossRef]
37. Kroemer, G.; Galluzzi, L.; Vandenabeele, P.; Abrams, J.; Alnemri, E.S.; Baehrecke, E.H.; Blagosklonny, M.V.; El-Deiry, W.S.; Golstein, P.; Green, D.R.; et al. Classification of cell death: Recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 1, 3–11. [CrossRef] [PubMed]
38. Panda, A.K.; Chakraborty, D.; Sarkar, I.; Khan, T.; Sa, G. New insights into therapeutic activity and anticancer properties of curcumin. J. Exp. Pharmacol. 2017, 9, 31–45. [CrossRef] [PubMed]
39. Amaral, L.; Spengler, G.; Molnar, J. Identification of Important Compounds Isolated from Natural Sources that Have Activity against Multidrug-resistant Cancer Cell Lines: Effects on Proliferation, Apoptotic Mechanism and the Efflux Pump Responsible for Multi-resistance Phenotype. Anticancer Res. 2016, 11, 5665–5672. [CrossRef] [PubMed]
40. Khan, M.; Rasul, A.; Yi, F.; Zhong, L.; Ma, T. Jaceosidin Induces P53-Dependent G2/M Phase Arrest in U87 Glioblastoma Cells. Asian Pac. J. Cancer Prev. 2011, 12, 3235–3238. [PubMed]
41. Gire, V.; Dulić, V. Senescence from G2 arrest, revisited. Cell Cycle 2015, 3, 297–304. [CrossRef] [PubMed]
42. Dutto, I.; Tillhon, M.; Cazzalini, O.; Stivala, L.A.; Prosperi, E. Biology of the cell cycle inhibitor p21CDKN1A: Molecular mechanisms and relevance in chemical toxicology. Arch. Toxicol. 2015, 2, 155–178. [CrossRef] [PubMed]
43. Ohkoshi, S.; Yano, M.; Matsuda, Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J. Gastroenterol. 2015, 42, 12150–12156. [CrossRef] [PubMed]
44. Zou, G.; Gao, Z.; Wang, J.; Zhang, Y.; Ding, H.; Huang, J.; Chen, L.; Guo, Y.; Jiang, H.; Shen, X. Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPAR?. Biochem. Pharmacol. 2008, 6, 1381–1392. [CrossRef] [PubMed]
45. Siegmund, D.; Lang, I.; Wajant, H. Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2. FEBS J. 2016, 284, 1131–1159. [CrossRef] [PubMed]
46. Chen, W.; Hou, J.; Yin, Y.; Jang, J.; Zheng, Z.; Fan, H.; Zou, G. ?-Bisabolol induces dose- and time-dependent apoptosis in HepG2 cells via a Fas- and mitochondrial-related pathway, involves p53 and NF?B. Biochem. Pharmacol. 2010, 2, 247–254. [CrossRef] [PubMed]
47. Yin, Y.; Chen, W.; Tang, C.; Ding, H.; Jang, J.; Weng, M.; Cai, Y.; Zou, G. NF-?B, JNK and p53 pathways are involved in tubeimoside-1-induced apoptosis in HepG2 cells with oxidative stress and G2/M cell cycle arrest. Food Chem. Toxicol. 2011, 12, 3046–3054. [CrossRef] [PubMed]
48. Hikita, H.; Kodama, T.; Tanaka, S.; Saito, Y.; Nozaki, Y.; Nakabori, T.; Shimizu, S.; Hayashi, Y.; Li, W.; Shigekawa, M.; et al. Activation of the Mitochondrial Apoptotic Pathway Produces Reactive Oxygen Species and Oxidative Damage in Hepatocytes That Contribute to Liver Tumorigenesis. Cancer Prev. Res. 2015, 8, 693. [CrossRef] [PubMed]
49. Nakagawa-Goto, K.; Chen, J.-Y.; Cheng, Y.-T.; Lee, W.-L.; Takeya, M.; Saito, Y.; Lee, K.-H.; Shyur, L.-F. Novel sesquiterpene lactone analogues as potent anti-breast cancer agents. Mol. Oncol. 2016, 6, 921–937. [CrossRef] [PubMed]
50. Ivanova, D.; Zhelev, Z.; Aoki, I.; Bakalova, R.; Higashi, T. Overproduction of reactive oxygen species-obligatory or not for induction of apoptosis by anticancer drugs. Chin. J. Cancer Res. 2016, 4, 383–396. [CrossRef] [PubMed]
51. Redza-Dutordoir, M.; Averill-Bates, D.A. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim. Biophys. Acta 2016, 12, 2977–2992. [CrossRef] [PubMed]
52. Singh, V.; Ram, M.; Kumar, R.; Prasad, R.; Roy, B.K.; Singh, K.K. Phosphorylation: Implications in Cancer. Protein. J. 2017, 36, 1–6. [CrossRef] [PubMed]
53. Liu, M.; Zhao, G.; Cao, S.; Zhang, Y.; Li, X.; Lin, X. Development of Certain Protein Kinase Inhibitors with the Components from Traditional Chinese Medicine. Front. Pharmacol. 2017, 7, 523. [CrossRef] [PubMed]
54. Huang, C.-C.; Lin, K.-J.; Cheng, Y.-W.; Hsu, C.-A.; Yang, S.-S.; Shyur, L.-F. Hepatoprotective effect and mechanistic insights of deoxyelephantopin, a phyto-sesquiterpene lactone, against fulminant hepatitis. J. Nutr. Biochem. 2013, 3, 516–530. [CrossRef] [PubMed]
55. Polychronidou, G.; Karavasilis, V.; Pollack, S.M.; Huang, P.H.; Lee, A.; Jones, R.L. Novel therapeutic approaches in chondrosarcoma. Future Oncol. 2017, 13, 637–648. [CrossRef] [PubMed]
56. Tran, P.; Nguyen, C.; Klempner, S.J. Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes? Int. Neurourol. 2016, 20, S131–S140. [CrossRef] [PubMed]
57. Guerrero-Zotano, A.; Mayer, I.A.; Arteaga, C.L. PI3K/AKT/mTOR: Role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016, 4, 515–524. [CrossRef] [PubMed]
58. Zhang, W.; Ma, T.; Li, S.; Yang, Y.; Guo, J.; Yu, W.; Kong, L. Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules. Eur. J. Med. Chem. 2017, 125, 538–550. [CrossRef] [PubMed]
59. Yang, S.-T.; Yen, C.-J.; Lai, C.-H.; Lin, Y.-J.; Chang, K.-C.; Lee, J.-C.; Liu, Y.-W.; Chang-Liao, P.-Y.; Hsu, L.-S.; Chang, W.-C.; et al. SUMOylated CPAP is required for IKK-mediated NF-?B activation and enhances HBx-induced NF-?B signaling in HCC. J. Hepatol. 2013, 6, 1157–1164. [CrossRef] [PubMed]
60. Siveen, K.S.; Sikka, S.; Surana, R.; Dai, X.; Zhang, J.; Kumar, A.P.; Tan, B.K.H.; Sethi, G.; Bishayee, A. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. Biochim. Biophys. Acta 2014, 2, 136–154. [CrossRef] [PubMed]
61. Ramesh, V.; Selvarasu, K.; Pandian, J.; Myilsamy, S.; Shanmugasundaram, C.; Ganesan, K. NF?B activation demarcates a subset of hepatocellular carcinoma patients for targeted therapy. Cell. Oncol. 2016, 6, 523–536. [CrossRef] [PubMed]
62. Zhao, L.; Zhang, Y. miR-342–3p affects hepatocellular carcinoma cell proliferation via regulating NF-?B pathway. Biochem. Biophys. Res. Commun. 2015, 3, 370–377. [CrossRef] [PubMed]
63. Han, S.-S.; Yun, H.; Son, D.-J.; Tompkins, V.S.; Peng, L.; Chung, S.-T.; Kim, J.-S.; Park, E.-S.; Janz, S. NF-?B/STAT3/PI3K signaling crosstalk in iMyc(Eµ)B lymphoma. Mol. Cancer 2010, 9, 97. [CrossRef] [PubMed]